145 related articles for article (PubMed ID: 35194902)
1. Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients.
Tsironi T; Gaitanis G; Pappas C; Koutlas V; Dounousi E; Bassukas ID
Dermatol Ther; 2022 May; 35(5):e15405. PubMed ID: 35194902
[TBL] [Abstract][Full Text] [Related]
2. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract][Full Text] [Related]
3. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
4. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
Gaitanis G; Kalogeropoulos CD; Bassukas ID
Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
[TBL] [Abstract][Full Text] [Related]
5. Immunocryosurgery - an effective combinational modality for Bowen's disease.
Gaitanis G; Bassukas ID
Dermatol Ther; 2016 Sep; 29(5):334-337. PubMed ID: 27272913
[TBL] [Abstract][Full Text] [Related]
6. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
Nakuçi M; Bassukas ID
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
[TBL] [Abstract][Full Text] [Related]
7. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
8. Cryosurgery during imiquimod cream treatment ("immunocryosurgery") for Bowen's disease of the skin: a case series.
Gaitanis G; Mitsou G; Tsiouri G; Alexis I; Bassukas ID
Acta Derm Venereol; 2010 Sep; 90(5):533-4. PubMed ID: 20814639
[No Abstract] [Full Text] [Related]
9. Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma.
Gaitanis G; Bassukas I
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1117-21. PubMed ID: 25243268
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the inflammatory cells infiltrating basal cell carcinomas during immunocryosurgery.
Nomikos K; Lampri E; Spyridonos P; Bassukas ID
Arch Dermatol Res; 2019 Aug; 311(6):499-504. PubMed ID: 31115658
[TBL] [Abstract][Full Text] [Related]
11. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Aguilar M; de Troya M; Martin L; Benítez N; González M
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
[TBL] [Abstract][Full Text] [Related]
12. Cryosurgery and 5-Fluorouracil Combination Therapy for Treatment of Bowen's Disease and Superficial Basal Cell Carcinoma.
Nazarali S; Sajic D
J Drugs Dermatol; 2023 Dec; 22(12):1166-1171. PubMed ID: 38051856
[TBL] [Abstract][Full Text] [Related]
13. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
14. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
15. A Review of Immunocryosurgery and a Practical Guide to Its Applications.
Gaitanis G; Bassukas ID
Diseases; 2021 Oct; 9(4):. PubMed ID: 34698134
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream.
Wu JK; Siller G; Whitehead K
Australas J Dermatol; 2003 May; 44(2):123-5. PubMed ID: 12752186
[TBL] [Abstract][Full Text] [Related]
17. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
Cannon PS; O'Donnell B; Huilgol SC; Selva D
Br J Ophthalmol; 2011 Dec; 95(12):1682-5. PubMed ID: 20702431
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
Morton CA; Whitehurst C; McColl JH; Moore JV; MacKie RM
Arch Dermatol; 2001 Mar; 137(3):319-24. PubMed ID: 11255332
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
20. Multiple Bowen's diseases and basal cell carcinomas in a patient with acute promyelocytic leukemia treated with arsenic trioxide: A case report and effective treatment with photodynamic therapy.
Ding C; Ma YY; Wang P; Liu J
Dermatol Ther; 2018 Nov; 31(6):e12718. PubMed ID: 30239071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
